BAUDAX BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0103 USD | -8.04% |
|
-2.83% | -53.18% |
| Feb. 22 | Baudax Bio, Inc. Filed for Bankruptcy | CI |
| 2023 | Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Capitalization 1 | 64.71 | 26.5 | 18.54 | 1.765 |
| Enterprise Value (EV) 1 | 47.74 | 5.936 | 12.19 | 4.441 |
| P/E ratio | - | -0.26 x | -0.76 x | -0.02 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 53,752,130 x | 17,166,258 x | 1,390,481 x |
| EV / Revenue | - | 53,752,088 x | 17,166,252 x | 1,390,484 x |
| EV / EBITDA | -1.64 x | -0.49 x | -0.36 x | -0.05 x |
| EV / FCF | -1,811,097 x | -1,499,514 x | -572,591 x | -175,341 x |
| FCF Yield | -0% | -0% | -0% | -0% |
| Price to Book | -3.87 x | -3.32 x | 1.63 x | -0.21 x |
| Nbr of stocks (in thousands) | 6.68 | 18.7 | 60.4 | 555 |
| Reference price 2 | 9,688 | 1,414 | 306.9 | 3.180 |
| Announcement Date | 2/13/20 | 2/16/21 | 3/16/22 | 2/23/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | 0.493 | 1.08 | 1.269 |
| EBITDA 1 | -48.19 | -64.64 | -39.39 | -53.7 | -52.14 | -35.58 |
| EBIT 1 | -48.26 | -65.04 | -39.87 | -54.11 | -52.38 | -35.74 |
| Operating Margin | - | - | - | -10,975.05% | -4,849.63% | -2,816.63% |
| Earnings before Tax (EBT) 1 | -61.08 | -73.67 | -32.56 | -76.1 | -19.77 | -58.8 |
| Net income 1 | -61.08 | -73.67 | -32.56 | -76.1 | -19.77 | -58.8 |
| Net margin | - | - | - | -15,436.11% | -1,830.46% | -4,633.18% |
| EPS | - | - | - | -5,504 | -405.4 | -177.3 |
| Free Cash Flow | - | -61.15 | -35.73 | -17.67 | -32.38 | -10.06 |
| FCF margin | - | - | - | -3,584.63% | -2,998% | -793.02% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/5/19 | 11/5/19 | 2/13/20 | 2/16/21 | 3/16/22 | 2/23/23 |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.201 | 0.281 | 0.4 | 0.422 | 0.3 | 0.238 | 0.31 | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -16.32 | -16.38 | 30.01 | - | -6.972 | - | -8.6 | -4.688 | -7.045 | -1.776 |
| Operating Margin | -8,117.41% | -5,829.18% | 7,503% | - | -2,324% | - | -2,774.19% | - | - | - |
| Earnings before Tax (EBT) | -15.33 | -16.96 | 27.01 | - | -7.531 | - | -9.249 | 11.4 | -7.301 | - |
| Net income 1 | -15.33 | -16.96 | 27.01 | - | -7.531 | - | -9.249 | 11.4 | -7.375 | -1.934 |
| Net margin | -7,626.37% | -6,036.3% | 6,753% | - | -2,510.33% | - | -2,983.55% | - | - | - |
| EPS 2 | -280.0 | -280.0 | 532.4 | -126.8 | -42.00 | -98.80 | -12.33 | 4.910 | -1.510 | -0.3000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/5/21 | 11/4/21 | 3/16/22 | 5/5/22 | 8/11/22 | 11/8/22 | 2/23/23 | 5/11/23 | 8/16/23 | 11/20/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | 2.68 |
| Net Cash position | - | - | 17 | 20.6 | 6.35 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.0752 x |
| Free Cash Flow | - | -61.1 | -35.7 | -17.7 | -32.4 | -10.1 |
| ROE (net income / shareholders' equity) | - | 113% | 76.5% | 483% | 2,514% | 1,067% |
| ROA (Net income/ Total Assets) | - | -120% | -55.9% | -55% | -53.7% | -70.6% |
| Assets 1 | - | 61.42 | 58.29 | 138.3 | 36.84 | 83.31 |
| Book Value Per Share | - | - | -2,504 | -426.0 | 188.0 | -14.90 |
| Cash Flow per Share | - | - | 2,656 | 872.0 | 226.0 | 3.240 |
| Capex 1 | 0.77 | 3.37 | 1.32 | 0.64 | 0.2 | 0.02 |
| Capex / Sales | - | - | - | 129.61% | 18.8% | 1.58% |
| Announcement Date | 11/5/19 | 11/5/19 | 2/13/20 | 2/16/21 | 3/16/22 | 2/23/23 |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -53.18% | 540K | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- BXRXQ Stock
- Financials Baudax Bio, Inc.
